Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-745bb68f8f-b95js Total loading time: 0 Render date: 2025-01-09T13:30:05.483Z Has data issue: false hasContentIssue false

16 - The European Prevention of Alzheimer’s Disease Program: A Public–Private Partnership to Facilitate the Secondary Prevention of Alzheimer’s Disease Dementia

from Section 3 - Alzheimer’s Disease Clinical Trials

Published online by Cambridge University Press:  03 March 2022

By
Craig W. Ritchie
Edited by
Jeffrey Cummings ,
Jefferson Kinney  and
Howard Fillit
Jeffrey Cummings
Affiliation:
University of Nevada, Las Vegas
Jefferson Kinney
Affiliation:
University of Nevada, Las Vegas
Howard Fillit
Affiliation:
Alzheimer’s Drug Discovery Foundation
Get access

Summary

The ongoing European Prevention of Alzheimer’s Dementia Programme (EPAD) was established in 2015 to create a platform for Phase 2 testing of interventions for the secondary prevention of Alzheimer’s disease (AD) dementia. This initiative was the largest of its kind globally. The original funding from the Innovative Medicines Initiative ensured that through their public-private partnership model, the programme benefited from expertise, know-how, and resources from academia, the pharmaceutical arena and third sector. Setting the vision, managing the innovative programme and operationalising scores of crucial and interdependent elements was a substantial governance and project management undertaking. The programme is ongoing with data and samples accessible through state-of-the-art systems in partnership with the Alzheimer’s Disease Data Interoperability programme. Follow-up of research participants is being organised and their involvement in a range of clinical trials is being facilitated via collaboration with the Global Alzheimer’s Platform. The challenges and lessons learned from EPAD are important as the field continued to advance and new therapies are developed.

Keywords

Alzheimer’s diseaseEPADplatform trialspublic-private partnershipsbiological samplesregistry
Type
Chapter
Information
Alzheimer's Disease Drug Development
Research and Development Ecosystem
 , pp. 190 - 206
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ritchie, CW, Molinuevo, JL, Satlin, A, et al. The European Prevention of Alzheimer’s Dementia (EPAD) Consortium: a platform to enable the secondary prevention of Alzheimer’s dementia through improved proof of concept trials. Lancet Psychiatry 2016; 3: 179–86.CrossRefGoogle Scholar
Gregory, S, Wells, K, Forsyth, K, et al. Research participants as collaborators: background, experience and policies from the PREVENT Dementia and EPAD programmes. Dementia 2018; 17: 1045–54.CrossRefGoogle ScholarPubMed
Ritchie, K, Ritchie, CW. The PREVENT study: a prospective cohort study to identify mid-life biomarkers of late-onset Alzheimer’s disease. BMJ Open 2012; 2: e001893.CrossRefGoogle ScholarPubMed
Vermunt, L, Veal, CD, Ter Meulen, L, et al. European Prevention of Alzheimer’s Dementia Registry: recruitment and prescreening approach for a longitudinal cohort and prevention trials. Alzheimers Dement 2018; 14: 837–42.CrossRefGoogle ScholarPubMed
Solomon, A, Kivipelto, M, Molinuevoet, JL, al. European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study (EPAD LCS): study protocol. BMJ Open 2018; 8: e021017.Google Scholar
ten Kate, M, Ingala, S, Schwarz, A, et al. Secondary prevention of Alzheimer’s dementia: neuroimaging contributions. Alzheimers Res Ther 2018; 10: 112.CrossRefGoogle Scholar
Ritchie, K, Ropacki, M, Albala, B, et al. Recommended cognitive outcomes in preclinical Alzheimer’s disease: consensus statement from the European Prevention of Alzheimer’s Dementia project. Alzheimers Dement 2017; 13: 186–95.CrossRefGoogle ScholarPubMed
Mortamais, M, Ash, J, Harrison, J, et al. Detecting cognitive changes in preclinical Alzheimer’s disease: a review of its feasibility. Alzheimers Dement 2017; 13: 468–92.CrossRefGoogle ScholarPubMed
Ritchie, K, Carriere, I, Howett, D, et al. Allocentric and egocentric spatial processing in middle-aged adults at high risk of late-onset Alzheimer’s disease: the PREVENT Dementia Study. J Alzheimers Dis 2018; 65: 885–96.CrossRefGoogle ScholarPubMed
Ritchie, CW, Muniz-Terrera, G, Kivipelto, M, et al. The European Prevention of Alzheimer’s Dementia (EPAD) longitudinal cohort study: baseline data release V500.0. J Prev Alzheimers Dis 2019; 7: 8–13.Google Scholar
Ingala, S, De Boer, C, Masselink, LA, the EPAD consortium. Application of the ATN classification scheme in a population without dementia: findings from the EPAD cohort. Alzheimers Dement 2021;DOI: http://doi.org/10.1002/alz.12292.Google Scholar
Angus, D, Alexander, B, Berry, S, et al. Adaptive platform trials: definition, design, conduct, and reporting considerations. Nat Rev Drug Discov 2019; 18: 797–807.Google Scholar
Frisoni, G, Ritchie, C, Carrera, E, et al. Re-aligning scientific and lay narratives of Alzheimer’s disease. Lancet Neurol 2019; 18: 918–19.Google Scholar
Frisoni, GB, Molinuevo, JL, Altomare, D, et al. Precision prevention of Alzheimer’s and other dementias: anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. Alzheimers Dement 2020; 16: 1457–68.CrossRefGoogle ScholarPubMed
Ritchie, CW, Russ, TC, Banerjee, S, et al. The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease. Alzheimers Res Ther 2017; 9: 85.CrossRefGoogle ScholarPubMed
Jack, CR Jr., Bennett, DA, Blennow, K, et al. NIA–AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018; 14: 535–62.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×